Physician profile
Morris Hanan
NPI 1770576076
$2,860.48
in general payments reported to CMS, 2019-2025
19 companies · $501 in 2025
The $501 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $179 · 2021: $524 · 2022: $540 · 2023: $591 · 2024: $112 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $552.54 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.28 | 2019-2022 | |
| Boston Scientific Corporation | $333.20 | 2021-2024 | Compliance Endokit, Orcapod |
| Janssen Scientific Affairs, LLC | $317.82 | 2019-2023 | Stelara |
| Janssen Biotech, INC. | $303.61 | 2021-2023 | Stelara |
| Medical Device Business Services, INC. | $147.58 | 2023 | Linx Reflux Management System |
| Gilead Sciences, INC. | $121.87 | 2019 | |
| Lilly USA, LLC | $120.18 | 2025 | |
| Phathom Pharmaceuticals, INC. | $120.17 | 2025 | Voquezna |
| Ardelyx, INC. | $100.67 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $99.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $87.56 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.35 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $39.94 | 2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $30.71 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $23.64 | 2025 | |
| Allergan, INC. | $18.69 | 2019 | |
| Madrigal Pharmaceuticals | $18.59 | 2024 | Resmetirom |
| Regeneron Healthcare Solutions, INC. | $14.58 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Hanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.